This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''5-Methoxy-N,N-diisopropyltryptamine''' (also known as '''5-MeO-DiPT''', '''Foxy''', and '''Foxy Methoxy''') is a novel [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class that produces [[psychedelic]] effects when [[administered]]. It is related in structure to [[DiPT]] and [[5-MeO-MiPT]].
'''5-Methoxy-N,N-diisopropyltryptamine''' (also known as '''5-MeO-DiPT''', '''Foxy''', and '''Foxy Methoxy''') is a novel [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class that produces [[psychedelic]] effects when [[administered]]. It is related in structure to [[DiPT]] and [[5-MeO-MiPT]].
The first human trials of 5-MeO-DiPT were undertaken by [[Alexander Shulgin]] in 1975.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p176 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref> who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981.<ref>Shulgin, AT; Carter, MF. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1 Jan 1981, 4 (5), 363–369 | https://www.ncbi.nlm.nih.gov/pubmed/6949674</ref> A summary of the synthesis and reports of human use is included in Shulgin's 1997 book ''[[TiHKAL]]'' ("Tryptamines I Have Known And Loved").<ref name="TiHKAL">https://erowid.org/library/books_online/tihkal/tihkal.shtml</ref>
The first human trials of 5-MeO-DiPT were undertaken by [[Alexander Shulgin]] in 1975.<ref>{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes I (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf|page=176|place=Lafayette, CA|year=1976}}</ref> who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981.<ref>{{cite journal|last1=Shulgin|first1=A. T.|author-link1=Alexander Shulgin|last2=Carter|first2=M. F.|title=N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity|journal=Communications in psychopharmacology|issn=0145-5699|oclc=3012956|pmid=6949674|year=1980|volume=4|issue=5|pages=363-369}}</ref> A summary of the synthesis and reports of human use is included in Shulgin's 1997 book ''[[TiHKAL]]'' ("Tryptamines I Have Known And Loved").<ref name="Shulgin1997">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|date=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|ref=harv}}</ref>
Anecdotal reports characterize the effects of this compound as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, [[DiPT]].
Anecdotal reports characterize the effects of this compound as highly [[stimulating]] and mildly [[entactogenic]], lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to [[increased libido|enhance libido]] and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, [[DiPT]].
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a [[research chemical]]. It is highly advised to use [[harm reduction practices]] if using this substance.
Very little is known about the pharmacological properties, metabolism, and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a [[research chemical]]. It is highly advised to use [[harm reduction practices]] if using this substance.
==Chemistry==
==Chemistry==
Line 17:
Line 17:
==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
5-MeO-DiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]], although additional mechanisms of action such as [[MAOI]]s may also be involved.<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811 / https://www.ncbi.nlm.nih.gov/pubmed/17223101</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT<sub>2A</sub> receptor agonism, although additional mechanisms of action such as monoamine oxidase inhibition (MAOI) may also be involved.<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref> The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT<sub>1A</sub> receptor.<ref>{{cite journal | vauthors=((Ray, T. S.)) | veditors=((Manzoni, O. J.)) | journal=PLoS ONE | title=Psychedelics and the Human Receptorome | volume=5 | issue=2 | pages=e9019 | date=2 February 2010 | url=https://dx.plos.org/10.1371/journal.pone.0009019 | issn=1932-6203 | doi=10.1371/journal.pone.0009019}}</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
5-MeO-DiPT is neurotoxic in rats.<ref name="Noworyta-Sokolowska2016">{{cite journal|title=Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats|pmid=27461536|pmc=5047954|doi=10.1007/s12640-016-9654-0|first1=K.|last1=Noworyta-Sokołowska|first2=K.|last2=Kamińska|first3=G.|last3=Kreiner|first4=Z.|last4=Rogóż|first5=K.|last5=Gołembiowska|journal=Neurotoxicity Research|issn=1029-8428|eissn=1476-3524|oclc=50166444|volume=30|pages=606–619|year=2016|issue=4}}</ref></ref>
==Subjective effects==
==Subjective effects==
Line 70:
Line 72:
*'''[[Effect::Delusion]]'''
*'''[[Effect::Delusion]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Emotion enhancement]]'''
*'''[[Effect::Increased libido]]'''
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased music appreciation]]'''
Line 90:
Line 93:
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently no anecdotal reports that describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because 5-MeO-DiPT is a [[research chemical]] with very little history of human usage. The neurotoxic effects has been studies in rats.<ref>https://www.ncbi.nlm.nih.gov/pubmed/27461536</ref>
The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context, and the exact [[Toxicity::toxic dose is unknown]]. This is because 5-MeO-DiPT is a [[research chemical]] with very little history of human usage. The neurotoxic effects have been studied in rats.<ref name="Noworyta-Sokolowska2016"/>
Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
Line 103:
Line 107:
===Overdose===
===Overdose===
Excessive doses have caused [[nausea]], vomiting, agitation, [[decreased blood pressure]], [[pupil dilation]], [[increased heart rate]], and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.<ref>R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 975-976.</ref> A 24-year-old man also died of this compound being administered into the colon.
Excessive doses have caused [[nausea]], vomiting, agitation, [[decreased blood pressure]], [[pupil dilation]], [[increased heart rate]], and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man, and another one died 3–4 hours after an apparent rectal overdose.<ref>{{cite book|author=Randall C. Baselt|title=Disposition of Toxic Drugs and Chemicals in Man|edition=8th|publisher=Biomedical Publications|location=Foster City, CA|year=2008|pages=975-976|issn=0009-9147|isbn=978-0-9626523-7-0}}</ref> A 24-year-old man also died of this compound being administered into the colon.
===Tolerance and addiction potential===
===Tolerance and addiction potential===
Like other [[serotonergic psychedelic|serotonergic psychedelics]], 5-MeO-DiPT is [[Addiction potential::not habit-forming]].
Like other [[serotonergic psychedelic|serotonergic psychedelics]], 5-MeO-DiPT is [[Addiction potential::not habit-forming]].
Tolerance to the effects of 5-MeO-DiPT builds [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-DiPT all psychedelics will have a reduced effect.
Tolerance to the effects of 5-MeO-DiPT builds [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 5-MeO-DiPT, all psychedelics will have a reduced effect.
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Psychedelics}}
{{DangerousInteractions/5-MeO-xxT}}
5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI).<ref>https://www.ncbi.nlm.nih.gov/pubmed/23244432</ref><ref>https://www.ncbi.nlm.nih.gov/pubmed/3709792</ref> 5-MeO-DiPT and [[MAOIs]] are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.
5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI).<ref>{{cite journal|title=Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain|pmid=23244432|doi=10.2174/1871527311312010015|year=2013|volume=12|issue=1|pages=94-103|issn=1568-007X|journal=Drug Targets - CNS & Neurological Disorders|first1=S. K.|last1=Tayebati|first2=D.|last2=Tomassoni|first3=I. E.|last3=Nwankwo|first4=A.|last4=Di Stefano|first5=P.|last5=Sozio|first6=L. S.|last6=Cerasa|first7=F.|last7=Amenta}}</ref><ref>{{cite journal|title=Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug|year=1986|volume=41|issue=4|pages=325-334|pmid=3709792|first1=M.|last1=Trabucchi|first2=S.|last2=Govoni|first3=F.|last3=Battaini|journal=Il Farmaco, Edizione Scientifica|issn=0430-0920|oclc=1064491979}}</ref> 5-MeO-DiPT and [[MAOIs]] are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.
==Legal status==
==Legal status==
* '''Brazil:''' Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
* '''China:''' 5-MeO-DiPT is illegal in China.<ref>http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|language=pt|access-date=January 8, 2020|publisher=Agência Nacional de Vigilância Sanitária (Anvisa) [National Sanitary Surveillance Agency]|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7}}</ref>
* '''Denmark:''' 5-MeO-DiPT is illegal in Denmark.{{citation needed}}
*'''China''': 5-MeO-DiPT is illegal in China.<ref>{{cite web|url=http://www.sfda.gov.cn/WS01/CL0056/130753.html|title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知|publisher=国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]|date=September 27, 2015|language=zh|archive-url=https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html|archive-date=September 6, 2017|access-date=August 19, 2020}}</ref>
* '''Greece:''' 5-MeO-DiPT is illegal in Greece.{{citation needed}}
*'''Denmark''': 5-MeO-DiPT is illegal in Denmark.{{citation needed}}
* '''Germany:''' 5-MeO-DiPT is controlled under BtMG Anlage I, making it illegal to manufacture, import, possess, sell, or transfer it without a license.<ref>https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html</ref>
*'''Germany''': 5-MeO-DiPT is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of October 10, 2000.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D__1576702069328|title=Vierzehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 18, 2019|date=September 27, 2000|publication-date=September 30, 2000|pages=1414-1415|work=Bundesgesetzblatt Jahrgang 2000 Teil I Nr. 44|language=de|issn=0341-1095}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref>
* '''Japan:''' 5-MeO-DiPT is illegal in Japan.{{citation needed}}
*'''Greece''': 5-MeO-DiPT is illegal in Greece.{{citation needed}}
* '''Latvia:''' 5-MeO-DiPT is illegal in Latvia.{{citation needed}}
*'''Japan''': 5-MeO-DiPT is illegal in Japan.{{citation needed}}
* '''New Zealand:''' 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>
*'''Latvia''': 5-MeO-DiPT is illegal in Latvia.{{citation needed}}
* '''Singapore:''' 5-MeO-DiPT is illegal in Singapore.{{citation needed}}
*'''New Zealand''': 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.<ref>{{cite web|url=http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576|title=Schedule 1: Class A controlled drugs|access-date=September 19, 2020|work=Misuse of Drugs Act 1975|publisher=Parliamentary Counsel Office (PCO)}}</ref>
* '''Sweden:''' 5-MeO-DiPT is illegal in Sweden.<ref>http://www.notisum.se/rnp/sls/sfs/20040696.pdf</ref>
*'''Singapore''': 5-MeO-DiPT is illegal in Singapore.{{citation needed}}
*'''United Kingdom:''' 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3</ref>, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e</ref>
*'''Sweden''': 5-MeO-DiPT is illegal in Sweden.<ref>{{cite web|title=Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor|url=http://www.notisum.se/rnp/sls/sfs/20040696.pdf|id=SFS 2004:696|language=sv|date=August 19, 2004|publication-date=September 7, 2004}}</ref>
* '''United States:''' 5-MeO-DiPT is a Schedule 1 controlled substance.{{citation needed}}
*'''Switzerland''': 5-MeO-DiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': 5-MeO-DiPT is a Schedule 1 controlled substance. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.<ref>{{Citation | title=Schedules of Controlled Substances: Placement of Alpha- Methyltryptamine and 5-Methoxy-N,N-Diisopropyltryptamine Into Schedule I | url=https://www.deadiversion.usdoj.gov/fed_regs/rules/2004/fr0929.htm}}</ref>
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
5-Methoxy-N,N-diisopropyltryptamine (also known as 5-MeO-DiPT, Foxy, and Foxy Methoxy) is a novel psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is related in structure to DiPT and 5-MeO-MiPT.
The first human trials of 5-MeO-DiPT were undertaken by Alexander Shulgin in 1975.[1] who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981.[2] A summary of the synthesis and reports of human use is included in Shulgin's 1997 book TiHKAL ("Tryptamines I Have Known And Loved").[3]
Anecdotal reports characterize the effects of this compound as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, DiPT.
Very little is known about the pharmacological properties, metabolism, and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices if using this substance.
5-MeO-DiPT, or 5-methoxy-N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-DiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiPT).
5-MeO-DiPT is the N-substituted diisopropyl homolog of 5-MeO-MiPT.
The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as monoamine oxidase inhibition (MAOI) may also be involved.[4] The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT1A receptor.[5] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Stomach bloating - At higher dosages, this compound can induce severe stomach bloating within those who are susceptible to it. This can be partially to fully mitigated through the use of antacids.
There are currently no anecdotal reports that describe the effects of this compound within our experience index. Additional experience reports can be found here:
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context, and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a research chemical with very little history of human usage. The neurotoxic effects have been studied in rats.[6]
Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Excessive doses have caused nausea, vomiting, agitation, decreased blood pressure, pupil dilation, increased heart rate, and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man, and another one died 3–4 hours after an apparent rectal overdose.[7] A 24-year-old man also died of this compound being administered into the colon.
Tolerance to the effects of 5-MeO-DiPT builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 5-MeO-DiPT, all psychedelics will have a reduced effect.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
2C-T-X - Both classes of compounds can be unpredictable alone.
2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
DXM - Little information exists about this combination.
PCP - Little information exists about this combination. May increase risk of psychosis and excessive stimulation.
5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI).[8][9] 5-MeO-DiPT and MAOIs are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.
Legal status
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[10]
Germany: 5-MeO-DiPT is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[12] as of October 10, 2000.[13] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[14]
Switzerland: 5-MeO-DiPT is a controlled substance specifically named under Verzeichnis E.[17]
United Kingdom: 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.[18]
United States: 5-MeO-DiPT is a Schedule 1 controlled substance. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.[19]
↑Shulgin, A. T.; Carter, M. F. (1980). "N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity". Communications in psychopharmacology. 4 (5): 363–369. ISSN0145-5699. OCLC3012956. PMID6949674.
↑Randall C. Baselt (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 975–976. ISBN978-0-9626523-7-0. ISSN0009-9147.
↑Tayebati, S. K.; Tomassoni, D.; Nwankwo, I. E.; Di Stefano, A.; Sozio, P.; Cerasa, L. S.; Amenta, F. (2013). "Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain". Drug Targets - CNS & Neurological Disorders. 12 (1): 94–103. doi:10.2174/1871527311312010015. ISSN1568-007X. PMID23244432.
↑Trabucchi, M.; Govoni, S.; Battaini, F. (1986). "Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug". Il Farmaco, Edizione Scientifica. 41 (4): 325–334. ISSN0430-0920. OCLC1064491979. PMID3709792.
↑"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in 中文). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. Retrieved August 19, 2020.
. PMID 27461536.